

Dr. Wellman's Homoeopathic Laboratory Limited



REGD. OFFICE :

A-23, Mandakini Enclave, Alaknanda
G K-II, New Delhi-110019

Tel.: 011-40562329

drwellman@wellman.co.in

DR. WELLMAN'S HOMOEOPATHIC LABORATORY LIMITED

Regd. Office: A-23, Mandakini Enclave, Alaknanda, New Delhi-110019

Unaudited Financial Results for the Quarter/ Nine months ended 31.12.2011

Rs.in Lacs

S.No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2011	30.9.2011	31.12.2010	31.12.2011	31.12.2010	31.03.2011
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Sales/Income from Operations	15.50	12.40	26.98	49.10	96.46	84.81
	Other Operating Income	-	-	-	-	-	-
	Total Operating Income	15.50	12.40	26.98	49.10	96.46	84.81
2	Expenditure						
	a. (increase)/decrease in stock in trade	-	-	3.41	-	3.11	3.40
	b. Consumption of Raw Material/ Supervision charges	8.00	7.20	6.84	15.20	40.90	36.83
	c. Purchase of traded goods	-	-	-	4.12	-	-
	d. Employees Cost	1.78	2.06	4.08	5.09	5.94	15.61
	e. Marketing Expenses	0.24	0.42	6.57	0.66	6.57	11.00
	f. Compounding Fees/ Reinstatement Charges	7.00	-	-	17.35	-	-
	g. Depreciation	0.91	0.91	0.32	2.73	1.69	0.96
	h. Other Expenditure	1.94	1.28	5.23	6.91	13.02	12.68
	Total Expenditure	19.87	11.87	26.45	52.06	71.23	80.48
3	Profit from Operations before Other Income Interest & Exceptional Items(1-2)	(4.37)	0.53	0.53	(2.96)	25.23	4.33
4	Other Income	0.79	-	-	0.79	-	-
5	Profit before Interest & Exceptional Items (3+4)	(3.58)	0.53	0.53	(2.17)	25.23	4.33
6	Interest	0.05	0.06	-	0.16	0.08	0.06
7	Profit after Interest but before Exceptional items (5-6)	(3.63)	0.47	0.53	(2.33)	25.15	4.27
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary activities before tax (7+8)	(3.63)	0.47	0.53	(2.33)	25.15	4.27
10	Tax Expenses						
	Current Tax	-	-	-	-	-	-
11	Net Profit from Ordinary activities after tax(9-10)	(3.63)	0.47	0.53	(2.33)	25.15	4.27
12	Extraordinary Item(net of tax expense)	-	-	-	-	126.93	-
13	Net Profit for the Period(11-12)	(3.63)	0.47	0.53	(2.33)	152.08	4.27
14	Paid up Equity Share Capital (Face Value per share: Re. 10/-)	475.15	475.15	470.58	475.15	470.58	475.10
15	Reserves excluding Revaluation Reserves as per balance sheet of Previous Accounting Year	-	-	-	-	-	-
16	Earnings per Share (EPS)(not to be Annualized)						
	Basic EPS before Extraordinary items	(0.07)	0.01	0.01	(0.05)	0.49	0.08
	Diluted EPS before Extraordinary items	(0.07)	0.01	0.01	(0.05)	0.49	0.08
	Basic EPS after Extraordinary items	(0.07)	0.01	0.01	(0.05)	3.00	0.08
	Diluted EPS after Extraordinary items	(0.07)	0.01	0.01	(0.05)	3.00	0.08
17	Public Shareholding						
	Number of Shares	3,347,300	4,406,400	4,794,900	3,347,300	4,794,900	4,307,900
	Percentage of Shareholdings	66.06	86.96	94.63	66.06	94.63	85.02
18	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	Number of Shares	-	-	-	-	-	-
	Percentage of Shares(as a % of total Shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
	Percentage of Shares(as a % of total Share Capital of the Company)	-	-	-	-	-	-
	b) Non-Encumbered						
	Number of Shares	1,719,600	660,500	272,000	1,719,600	272,000	759,000
	Percentage of Shares (as % of Total shareholding of Promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100
	Percentage of Shares (as % of Total sharecapital of the Company.	33.94	13.04	-	33.94	5.37	14.98



Segment wise Revenue, Results and Capital Employed

S.No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2011	30.09.2011	31.12.2010	31.12.2011	31.12.2010	31.03.2011
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	a) Sale of Homoeopathic Medicines	-	-	26.98	-	96.46	59.97
	b) Sale of Traded Goods	-	-	-	5.94	-	-
	c) Advisory Services	15.50	12.40	-	43.16	-	24.84
	Net Sales/ Income from Operations	15.50	12.40	26.98	49.10	96.46	84.81
2	Segments Results						
	Profit from Operations before tax from each segments						
	a) Sale of Homoeopathic Medicines	-	-	0.53	-	25.23	10.07
	b) Sale of Traded Goods	-	-	-	1.82	-	-
	c) Advisory Services	(3.58)	0.53	-	6.36	-	(5.74)
	Total Profit/ (Loss)	(3.58)	0.53	0.53	8.18	25.23	4.33
	Less: 1) Interest and finance charges	0.05	0.06	-	0.16	0.08	0.06
	2) Other unallocable expenditure net off unallocable Income	-	-	-	10.35	(126.93)	-
	Total Profit before tax	(3.63)	0.47	0.53	(2.33)	152.08	4.27
3	Capital Employed						
	(Segment assets -Segment Liabilities)						
	a) Sale of Homoeopathic Medicines	24.39	25.35	76.17	24.39	76.17	44.62
	b) Sale of Traded Goods	5.94	5.94	-	5.94	-	-
	c) Advisory Services	43.57	45.01	-	43.57	-	30.33
	d) Unallocated						
	Total	73.90	76.30	76.17	73.90	76.17	74.95

Notes:

- 1 The above results were reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 3rd February, 2012 and limited review of the same has been carried out by the statutory auditors of the company
- 2 Details of number of investors complaints for the quarter ended 31st December , 2011:Beginning -2, Received - Nil
Disposed off - 1, Pending - 1
- 3 Figures of the previous period / year have been regrouped/re-arranged, wherever necessary

Dated : 3rd February 2012
Place : New Delhi

For Dr. Wellman's Homoeopathic Laboratory Ltd


 (Managing Director)



SADANA & CO.

CHARTERED ACCOUNTANTS

109, Vishal Chambers, Sector-18, Noida-201301

e-mail: sadanaca@gmail.com | Tel: + 91-120-2510287, Telefax: + 91-120-4235368

Annexure V to Clause 41 Limited Review Report

Review Report to:
The Board of Directors,
Dr. Wellman's Homoeopathic Laboratory Limited, New Delhi.

We have reviewed the accompanying statement of unaudited financial results of Dr. Wellman's Homoeopathic Laboratory Limited for the period ended 31st December 2011 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards (Note 1) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sadana & Company
Chartered Accountants


(CA Amit Bansal)
Partner
Membership No.098966

Place : Noida
Date : 31/01/2012

Note 1. The Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 and/or Accounting Standards issued by Institute of Chartered Accountants of India.